Annals Thoracic Surgery, Author Interviews, Biomarkers, Kidney Disease / 15.01.2015

MedicalResearch.com Interview with: Professeur Sidney Chocron Chef de Service Chirurgie Thoracique et Cardio-Vasculaire CHU de Besançon - Hôpital Jean Minjoz BESANCON Cedex Medical Research: What is the background for this study? What are the main findings? Prof. Chocron: Acute kidney injury (AKI) is one of the most frequent complications after cardiac surgery.There is a time delay between the onset of renal impairment and the resulting telltale increase in blood creatinine levels. Recent studies have underlined the promising properties of Neutrophil Gelatinase-Associated Lipocalin (NGAL). NGAL values early after surgery could predict the duration and severity of Acute Kidney Injury. In addition, NGAL can independently predict deteriorating renal function and could therefore be useful even in the context of pre-existing renal failure. We aimed to assess the predictive ability of plasma NGAL levels to identify deteriorations in renal function after cardiac surgery in patients with pre-existing renal failure. Medical Research: What are the main findings? Prof. Chocron: One hundred sixty six patients with pre-operative renal failure i.e pre-operative creatinine clearance ≤60 mL/min/1.73m2 according to the Cockcroft Gault formula, were included in the study. The threshold NGAL values at 6 hours after operation, as determined by ROC curve analysis was 155 ng/mL with a sensitivity of 79% and a specificity of 58%. By multivariate analysis at 6 hours, a history of hypertension (OR=3.2 [1.2 - 8.9]), occurrence of at least 1 post-operative complication (OR=4.5 [1.3 - 15]), and an NGAL value above 155 ng/mL (OR=7.1 [2.7 - 18]) were shown to be independent predictors of the occurrence of post-operative AKI. (more…)
Author Interviews, Breast Cancer, JNCI, Mayo Clinic / 14.12.2014

Dr. Matthew P. Goetz, MD Associate Professor of Pncology Mayo ClinicMedicalResearch.com Interview with: Dr. Matthew P. Goetz, MD Associate Professor of Pncology Mayo Clinic Medical Research: What is the background for this study? What are the main findings? Dr. Goetz: There has been conflicting data with regard to the importance of metabolism as measured by CYP2D6 genetic variation.   Two large “negative” studies were reported simultaneously in 2012 and these were referenced by guidelines that CYP2D6 should not be used to select hormonal therapy.   Our findings demonstrated that these studies were flawed in part based on analytical validity issues.  In short, the use of tumor tissue to derive CYP2D6 germline genotype leads to genotyping error in up to 45% of samples. (more…)
Author Interviews, Heart Disease / 16.09.2014

Muthiah Vaduganathan, MD MPH Department of Medicine Massachusetts General Hospital Boston, MassMedicalResearch.com Interview with: Muthiah Vaduganathan, MD MPH Department of Medicine Massachusetts General Hospital Boston, Mass Medical Research: What are the main findings of the study? Dr. Vaduganathan: Based on data from a large, multinational randomized controlled trial of patients hospitalized for heart failure and reduced ejection fraction (HFrEF), we conducted a retrospective analyses of the clinical profiles associated with baseline serum uric acid levels. Serum uric acid was commonly elevated in patients hospitalized for heart failure and reduced ejection fraction (mean ~9 mg/dL), especially in men and black patients. Higher uric acid levels were associated with lower systolic blood pressure and EF, higher natriuretic peptides, and more impaired renal function. After accounting for 24 known baseline covariates, serum uric acid was independently predictive of post-discharge mortality and rehospitalization in patients with relatively preserved renal function, but not in those with poor renal function. (more…)
Author Interviews, Biomarkers, Rheumatology / 12.06.2014

Dr Christian Beyer Department of Internal Medicine 3 - Rheumatology and Immunology University of Erlangen-Nuremberg, Germany.MedicalResearch.com: Interview with: Dr Christian Beyer Department of Internal Medicine 3 - Rheumatology and Immunology University of Erlangen-Nuremberg, Germany. MedicalResearch: What are the main findings of the study? Dr. Beyer: Our study aimed to identify specific micro RNAs as preditors for osteoarthritis. Osteoarthritis is a progressive and long-standing disease. It's early and very early stages are clinically silent, which means that patients do not experience symptoms or present with obvious signs of the disease. Preventive measures and early therapies, however, would be probably most effective in treating this very common condition. Thus, markers to identify individuals at risk for osteoarthritis or in early clinical stages are highly important, but are not available for clinical routine yet. Micro RNAs are group of molecules that have signaling functions in the human body and that can reflect states of disease and health. Since they are very stable and easily accessible in the peripheral blood (by venous puncture without complicated procedures like biopsies), the represent promising biomarkers in many different fields of medicine. In this context, we wondered if specific micro RNAs might predict the development of severe osteoarthritis. Indeed, we could identify thre micro RNAs, named mir-454, mir-885-5p and let-7e, out of a total of 377 micro RNAs, that help to predict the risk for developing severe osteoarthritis. (more…)
Author Interviews, Biomarkers, CHEST, Cleveland Clinic, Lung Cancer / 20.04.2014

Daniel I. Sessler, M.D. Michael Cudahy Professor and Chair, Department of Outcomes Research Cleveland Clinic, Cleveland,MedicalResearch.com Interview with: Daniel I. Sessler, M.D. Michael Cudahy Professor and Chair, Department of Outcomes Research Cleveland Clinic, Cleveland, OH MedicalResearch.com: What are the main findings of the study? Dr. Sessler: Free fatty acids, arachidonic acid and linoleic acid, and their metabolites hydroxyeicosatetraenoic acids (5-HETE, 11-HETE, 12-HETE, and 15-HETE) were 1.8 to 5.7-fold greater in 37 patients with adenocarcinoma versus 111 patients without cancer (all P<0.001). Areas under the receiver operating characteristics (ROC) curve were significantly greater than 0.50 discriminating lung cancer patients and controls for all biomarkers and phospholipids, and ranged between 0.69 and 0.82 (all P<0.001) for lung cancer patients versus controls. Arachidonic acid, linoleic acid, and 15-HETE showed sensitivity and specificity >0.70 at the best cutpoint. Concentrations of free fatty acids and their metabolites were similar in 18 squamous-cell carcinoma patients and 54 non-cancer controls. (more…)
Author Interviews, Biomarkers, Cancer Research, Radiation Therapy / 02.04.2014

Jan Akervall, M.D., Ph.D. Co-director, Head and Neck Cancer Multidisciplinary Clinic Beaumont Hospital, Royal Oak Clinical Director of Beaumont’s BioBankMedicalResearch.com Interview with: Jan Akervall, M.D., Ph.D. Co-director, Head and Neck Cancer Multidisciplinary Clinic Beaumont Hospital, Royal Oak Clinical Director of Beaumont’s BioBank MedicalResearch.com: What are the main findings of the study? Dr. Akervall: We identified biomarkers that can predict who will have an unfavorable response from radiation for head and neck cancer. These can be analyzed using standard laboratory techniques on biopsies that routinely are taken for diagnosis. (more…)
Author Interviews, Biomarkers, Diabetes, Diabetologia, Kidney Disease / 14.03.2014

Prof Samy Hadjadj: Université de Poitiers, UFR Médecine Pharmacie, Centre d’Investigation clinique, CHU de Poitiers, Centre d’Investigation clinique, Poitiers, FranceMedicalResearch.com Interview with: Prof Samy Hadjadj: Université de Poitiers, UFR Médecine Pharmacie, Centre d’Investigation clinique, CHU de Poitiers, Centre d’Investigation clinique, Poitiers, France MedicalResearch.com: What are the main findings of the study? Prof: Hadjadj: The study helps to establish sTNFR1 as a valid biomarker not only for renal outcomes in type 2 diabetes but also for all cause death. Interestingly the addition of sTNFR1 concentration to the UKPDS model outcome equation showed to add some clinical prognostic value to this model for all-cause death. (more…)
Author Interviews, General Medicine, Lung Cancer / 19.09.2013

MedicalResearch.com Interview with: Jie He, PhD, MD Director, Laboratory of Thoracic Surgery President, Cancer Institute & Hospital, Chinese Academy of Medical Sciences Chaoyang District, Beijing, 100021 MedicalResearch.com: What are the main findings of the study? Dr. Jie He:  The main findings of the study is that we have identified IDH1 as an effective plasma biomarker for the diagnosis of NSCLCs, particularly with high sensitivity and specificity in the diagnosis of lung adenocarcinoma. (more…)
Biomarkers, Cancer Research / 16.08.2013

MedicalResearch.com Interview with: Martin Köbel M.D. Assistant Professor, Pathology and Lab Medicine
Calgary Laboratory Services 9 3535 Research Road Nw Calgary, Alberta T2L 2K8 Canada MedicalResearch.com: What are the main findings of the study? Answer:  Ovarian carcinomas are now divided into five histological types, which differ with respect to biology and clinical behaviour. However, the histological type assessment varies from center to center. Our study emphasizes the need for a standardized method to identify them. Until such consistent approach is established, histological types from various centers may not comprise the same entities and studies will give inconsistent results. (more…)
Author Interviews, Diabetes / 02.05.2013

MedicalResearch.com: Dr. Kyoung-bok Min Department of Occupational and Environmental Medicine, Ajou University School of Medicine, Suwon, Republic of Korea MedicalResearch.com: What are the main findings of the study? Answer: The aim of this study was to investigate the prospective association of serum C-peptide with all-cause, cardiovascular disease, and coronary heart disease mortality in a non-diabetic population. We also estimated the observed mortality as C-peptide increased across the strata of glycated hemoglobin and fasting blood glucose. We found a linear association between serum C-peptide levels and death from all-cause and cause-specific mortality among adults without non-diabetes mellitus at baseline. Our finding suggests that elevated C-peptide levels may be a marker of subsequent mortality in non-diabetic subjects. (more…)